The tweet was deleted by the author.
But we saved everything 🙂.
Immuneering's Chief Business Officer, E.B. Brakewood, actively advanced the company's strategic goals at BIO Europe in Vienna last week.
Brakewood provided a company update and engaged in meetings with global leaders in the biopharma industry to discuss Immuneering's promising pipeline targeting MAPK driven tumors. Immuneering is focused on developing novel treatments that address significant unmet needs in oncology, and the company's participation in such influential events highlights its commitment to its mission and goals.
Immuneering’s presence at BIO Europe builds on its ongoing efforts to deepen connections with biotech leaders, as demonstrated during its engagement at the Galien Forum 2025. The company’s momentum in pursuing innovative oncology solutions also follows advancements highlighted through its research into pancreas disease, underscoring a broad commitment to tackling healthcare’s most pressing challenges.